Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 15
2003 32
2004 17
2005 44
2006 54
2007 46
2008 55
2009 66
2010 60
2011 52
2012 47
2013 57
2014 72
2015 67
2016 74
2017 75
2018 69
2019 88
2020 81
2021 93
2022 79
2023 24
Text availability
Article attribute
Article type
Publication date

Search Results

1,078 results
Results by year
Filters applied: . Clear all
Page 1
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
Yang BB, Kido A. Yang BB, et al. Clin Pharmacokinet. 2011 May;50(5):295-306. doi: 10.2165/11586040-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21456630 Review.
After subcutaneous administration, pegfilgrastim exhibits nonlinear pharmacokinetics and exposure to pegfilgrastim increases in more than a dose-proportional manner, suggesting that the clearance of pegfilgrastim decreases with increased dosing. ...As a resul …
After subcutaneous administration, pegfilgrastim exhibits nonlinear pharmacokinetics and exposure to pegfilgrastim increases i …
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V. Aapro M, et al. Support Care Cancer. 2017 Nov;25(11):3295-3304. doi: 10.1007/s00520-017-3842-1. Epub 2017 Aug 25. Support Care Cancer. 2017. PMID: 28842778 Free PMC article. Review.

It was agreed that pegfilgrastim and 11 days' filgrastim have similar efficacy and safety and that pegfilgrastim is preferred to < 11 days' filgrastim (and may be preferred to 11 days' filgrastim based on adherence and convenience); pegfilgrastim is not ap

It was agreed that pegfilgrastim and 11 days' filgrastim have similar efficacy and safety and that pegfilgrastim is preferred …
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Wang L, Baser O, Kutikova L, Page JH, Barron R. Wang L, et al. Support Care Cancer. 2015 Nov;23(11):3131-40. doi: 10.1007/s00520-015-2686-9. Epub 2015 Mar 29. Support Care Cancer. 2015. PMID: 25821144 Free PMC article. Review.
FN risk was also significantly reduced with pegfilgrastim PP versus filgrastim PP. Over all chemotherapy cycles, there was a numerical but statistically nonsignificant increase in the FN risk for lipegfilgrastim PP versus pegfilgrastim PP. Using MTC in cycle 1, PP w …
FN risk was also significantly reduced with pegfilgrastim PP versus filgrastim PP. Over all chemotherapy cycles, there was a numerica …
Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.
Cerchione C, Nappi D, Martinelli G. Cerchione C, et al. Support Care Cancer. 2021 Nov;29(11):6973-6980. doi: 10.1007/s00520-021-06266-x. Epub 2021 May 14. Support Care Cancer. 2021. PMID: 33990881 Free PMC article. Review.
Filgrastim is a human recombinant subcutaneous preparation of G-CSF, largely adopted in hematological supportive care as "on demand" (or secondary) prophylaxis to recovery from neutropenia and its infectious consequences during anti-myeloma treatment. On the contrary, pegfilgr
Filgrastim is a human recombinant subcutaneous preparation of G-CSF, largely adopted in hematological supportive care as "on demand" (or sec …
Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar.
Hoy SM. Hoy SM. BioDrugs. 2019 Feb;33(1):117-120. doi: 10.1007/s40259-019-00334-9. BioDrugs. 2019. PMID: 30701419 Review.
Pegfilgrastim-jmdb/MYL-1401H (FULPHILA) [hereafter referred to as pegfilgrastim-jmdb] is a biosimilar of the reference pegylated recombinant granulocyte colony-stimulating factor pegfilgrastim. ...The overall safety profile and immunogenic potential of the tw
Pegfilgrastim-jmdb/MYL-1401H (FULPHILA) [hereafter referred to as pegfilgrastim-jmdb] is a biosimilar of the reference pegylat
LA-EP2006: A Pegfilgrastim Biosimilar.
Hoy SM. Hoy SM. BioDrugs. 2019 Apr;33(2):229-232. doi: 10.1007/s40259-019-00348-3. BioDrugs. 2019. PMID: 30887256 Review.
LA-EP2006 (Ziextenzo()) is the fifth biosimilar of pegfilgrastim, a pegylated recombinant granulocyte colony-stimulating factor, to be approved in the EU. ...The tolerability and safety profile of and the incidence of anti-drug antibodies with LA-EP2006 were similar to tho …
LA-EP2006 (Ziextenzo()) is the fifth biosimilar of pegfilgrastim, a pegylated recombinant granulocyte colony-stimulating factor, to b …
Pegfilgrastim.
Curran MP, Goa KL. Curran MP, et al. Drugs. 2002;62(8):1207-13; discussion 1214-5. doi: 10.2165/00003495-200262080-00012. Drugs. 2002. PMID: 12010086 Review.
Pegfilgrastim is a covalent conjugant of filgrastim (a recombinant human granulocyte colony-stimulating factor) and monomethoxypolyethylene glycol. ...Serum concentrations of pegfilgrastim remain elevated during neutropenia but decline when the neutrophil count incr
Pegfilgrastim is a covalent conjugant of filgrastim (a recombinant human granulocyte colony-stimulating factor) and monomethoxypolyet
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
Blayney DW, Mohanlal R, Adamchuk H, Kirtbaya DV, Chen M, Du L, Ogenstad S, Ginn G, Huang L, Zhang Q. Blayney DW, et al. JAMA Netw Open. 2022 Jan 4;5(1):e2145446. doi: 10.1001/jamanetworkopen.2021.45446. JAMA Netw Open. 2022. PMID: 35084480 Free PMC article. Clinical Trial.
Plinabulin was well tolerated, with comparable safety to pegfilgrastim. CONCLUSIONS AND RELEVANCE: Plinabulin has comparable efficacy to pegfilgrastim for the prevention of CIN, with better safety and a better immunosuppressive profile. Plinabulin's same-day dosing …
Plinabulin was well tolerated, with comparable safety to pegfilgrastim. CONCLUSIONS AND RELEVANCE: Plinabulin has comparable efficacy …
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Blayney DW, Zhang Q, Feng J, Zhao Y, Bondarenko I, Vynnychenko I, Kovalenko N, Nair S, Ibrahim E, Udovista DP, Mohanlal R, Ogenstad S, Ette E, Du L, Huang L, Shi YK. Blayney DW, et al. JAMA Oncol. 2020 Nov 1;6(11):e204429. doi: 10.1001/jamaoncol.2020.4429. Epub 2020 Nov 12. JAMA Oncol. 2020. PMID: 32970104 Free PMC article. Clinical Trial.
OBJECTIVE: To assess the efficacy and safety of plinabulin compared with pegfilgrastim for the prevention of chemotherapy-induced neutropenia following docetaxel chemotherapy in patients with non-small lung cancer. ...CONCLUSIONS AND RELEVANCE: Single dose-per-cycle plinab …
OBJECTIVE: To assess the efficacy and safety of plinabulin compared with pegfilgrastim for the prevention of chemotherapy-induced neu …
NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim.
Kirshner JJ, McDonald MC 3rd, Kruter F, Guinigundo AS, Vanni L, Maxwell CL, Reiner M, Upchurch TE, Garcia J, Morrow PK. Kirshner JJ, et al. Support Care Cancer. 2018 Apr;26(4):1323-1334. doi: 10.1007/s00520-017-3959-2. Epub 2017 Nov 16. Support Care Cancer. 2018. PMID: 29147854 Free PMC article. Clinical Trial.
PURPOSE: Mild-to-moderate bone pain is a commonly reported adverse event (AE) associated with pegfilgrastim. We evaluated the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on pegfilgrastim-associated bone pain. METHODS: In this open-labe …
PURPOSE: Mild-to-moderate bone pain is a commonly reported adverse event (AE) associated with pegfilgrastim. We evaluated the effect …
1,078 results